Pancreatic enzyme replacement therapy and coefficient of fat absorption in children and adolescents with cystic fibrosis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 61, Issue 3, 2015, Pages 355-360

  Woestenenk, Janna W ^a   Van Der Ent, Cornelis K ^a   Houwen, Roderick H J ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Cystic Fibrosis Centre Utrecht   (Netherlands)

Author keywords

Coefficient of fat absorption; Cystic fibrosis; Pancreatic enzyme replacement therapy

Indexed keywords

TRIACYLGLYCEROL LIPASE; FAT;

ARTICLE; CHILD; CLINICAL FEATURE; CYSTIC FIBROSIS; DIETARY INTAKE; ENTERIC FEEDING; ENZYME REPLACEMENT; FAT INTAKE; FEMALE; HUMAN; LIPID ABSORPTION; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL ASSESSMENT; PANCREAS INSUFFICIENCY; PANCREATIC ENZYME REPLACEMENT THERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; ADOLESCENT; COMPLICATION; CROSS-SECTIONAL STUDY; DRUG EFFECTS; ENZYMOLOGY; EXOCRINE PANCREATIC INSUFFICIENCY; GASTROINTESTINAL ABSORPTION; INFANT; MEDICAL RECORD; METABOLISM; NONPARAMETRIC TEST; PANCREAS; PATHOPHYSIOLOGY; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; DIET RECORDS; ENZYME REPLACEMENT THERAPY; EXOCRINE PANCREATIC INSUFFICIENCY; FATS; FEMALE; GASTROINTESTINAL ABSORPTION; HUMANS; INFANT; LIPASE; MALE; PANCREAS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84974823899     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000784     Document Type: Article

References (35)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373:1891-904.
2. Corey M, McLaughlin FJ, Williams M, et al. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988;41:583-91.
3. Yen EH, Quinton H, Borowitz D. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr 2013;162:530-5.
4. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002;35:246-59.
5. Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: A European Consensus. J Cyst Fibros 2002;1:51-75.
6. Littlewood JM, Wolfe SP, Conway SP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol 2006; 41:35-49.
7. Nevo Foundation. NEVO Table, Dutch Food Composition Table. The Hague: The Netherlands Nutrition Centre Foundation; 2006.
8. Borowitz D, Konstan MW, O'Rourke A, et al. Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther 2007;12:47-52.
9. Francisco MP, Wagner MH, Sherman JM, et al. Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002;35:79-83.
10. Cohen JR, Schall JI, Ittenbach RF, et al. Fecal elastase: pancreatic status verification and influence on nutritional status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2005;40:438-44.
11. Kalnins D, Corey M, Ellis L, et al. Combining unprotected pancreatic enzymes with pH-sensitive enteric-coated microspheres does not improve nutrient digestion in patients with cystic fibrosis. J Pediatr 2005;146:489-93.
12. Kalnins D, Ellis L, Corey M, et al. Enteric-coated pancreatic enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis. J Pediatr Gastroenterol Nutr 2006; 42:256-61.
13. Durie P, Kalnins D, Ellis L. Uses and abuses of enzyme therapy in cystic fibrosis. J R Soc Med 1998;91 (suppl 34):2-13.
14. Littlewood JM, Wolfe SP. Control of malabsorption in cystic fibrosis. Paediatr Drugs 2000;2:205-22.
15. Dodge JA. Pancreatic enzyme therapy in cystic fibrosis. Expert Rev Respir Med 2008;2:681-3.
16. Van de Vijver, E, Desager K, Mulberg AE, et al. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT. J Pediatr Gastroenterol Nutr 2011;53:61-4.
17. Baker SS, Borowitz D, Baker RD. Pancreatic exocrine function in patients with cystic fibrosis. Curr Gastroenterol Rep 2005;7:227-33.
18. Lowdon J, Goodchild MC, Ryley HC, et al. Maintenance of growth in cystic fibrosis despite reduction in pancreatic enzyme supplementation. Arch Dis Child 1998;78:377-8.
19. Schibli S, Durie PR, Tullis ED. Proper usage of pancreatic enzymes. Curr Opin Pulm Med 2002;8:542-6.
20. Lisowska A, Kaminska B, Grzymislawski M, et al. Unresponsive or non-compliant steatorrhea in cystic fibrosis? J Cyst Fibros 2006;5: 253-5.
21. Fridge JL, Conrad C, Gerson L, et al. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr 2007;44:212-8.
22. Borowitz D. Update on the evaluation of pancreatic exocrine status in cystic fibrosis. Curr Opin Pulm Med 2005;11:524-7.
23. Van der Doef, HP, Kokke FT, Beek FJ, et al. Constipation in pediatric cystic fibrosis patients: An underestimated medical condition. J Cyst Fibros 2010;9:59-63.
24. De Lisle, RC, Roach E, Jansson K. Effects of laxative and N-Acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2007;293:577-84.
25. De Lisle, RC, Sewell R, Meldi L. Enteric circular muscle dysfunction in the cystic fibrosis mouse small intestine. Neurogastroenterol Motil 2010;22:341-87.
26. O'Brien S, Mulcahy H, Fenlon H, et al. Intestinal bile acid malabsorption in cystic fibrosis. Gut 1993;34:1137-41.
27. Strandvik B, Einarsson K, Lindblad A, et al. Bile acid kinetics and biliary lipid composition in cystic fibrosis. J Hepatol 1996;25: 43-8.
28. Debray D, Kelly D, Houwen R, et al. Best practice guidance for the diagnosis and management of cystic fibrosis-Associated liver disease. J Cyst Fibros 2011;10(Suppl. 2):29-36.
29. Armstrong MJ, Carey MC. The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res 1982;23:70-80.
30. Colombo C, Battezzati PM, Podda M, et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996;23:1484-90.
31. Merli M, Bertasi S, Servi R, et al. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: A randomized, placebo-controlled, crossover trial. J Pediatr Gastroenterol Nutr 1994;19:198-203.
32. Van der Doef, HP, Arets HG, Froeling SP, et al. Gastric acid inhibition for fat malabsorption or gastroesophageal reflux disease in cystic fibrosis: longitudinal effect on bacterial colonization and pulmonary function. J Pediatr 2009;155:629-33.
33. Hendriks JJ, Kester AD, Donckerwolcke R, et al. Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. Pediatr Pulmonol 2001;31:59-66.
34. Sander-Struckmeier S, Beckmann K, Janssen-van SG, et al. Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON(R)) in patients with pancreatic exocrine insufficiency. Pancreas 2013;42:983-9.
35. Ng SM, Jones AP. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database Syst Rev 2003;2: CD003424.